and/or prazosin IO-' M to the incubation medium changed neither the number nor the affinity of the SS receptors in the frontoparietal cortex membranes. Phenylephrine or prazosin affected neither SS-LI content nor the basal or forskolin (FK)-stimulated AC activities in the frontoparietal cortex. In addition, SS caused an equal inhibition of AC activity in frontoparietal cortex membranes of phenylephrineand prazosintreated rats compared with the respective control group. Finally, phenylephrine and prazosin did not vary the pertussis toxin (FTX)-catalyzed ADP ribosylation of G,-and/or G,-proteins. These results suggest that the above-mentioned changes are related to the phenylephrine activation of al-adrenoceptors or to the blocking of these receptors by prazosin. In addition. these data provide further support for a functional interrelationship between the c~,-adrenergic and somatostatinergic systems in the rat frontoparietal cortex.
Phenylephrine
Prazosin Somatostatin receptors Adenylate cyclase G-proteins Frontoparietal cortex SOMATOSTATIN (SS), iirst identified as a tetradecapeptide in the hypothalamus (8), is one of the most highly concentrated and widely distributed peptides in the mammalian nervous system (17,26,46). In the central nervous system (CNS), SS is a neurotransmitter that regulates neuronal activity and the release of other transmitters (12,58). Significant amounts of SS have been detected in the cerebral cortex (15). In addition, cerebral cortex membranes contain one of the largest concentrations of SS receptors (29,37,40,52,57,6(l). Noradrenergic fibers originating in the locus coeruleus are also widely distributed in the cerebral cortex (9,24,32). In the rat neocortex, (Y, adrenoceptors have been localized by autoradiography to lamina I and lamina Va and Vc, sparing the layer Vb pyramidal cells (27) . Somatostatinergic and noradrenergic neurotransmission modulate neuronal firing (15,49). Seizure activity is one of the aspects of behavior affected by SS. Applied to rats, SS causes general tonic-clonic seizures that are mediated through local depression of EEG activities and/ or epileptic spiking in the cortex, hippocampus, and striatum (23). The central noradrenergic system also plays an important role in the regulation of cortical neuronal excitability (49). Drugs or lesions that deplete brain stores of noradrenaline (NA) are known to facilitate seizures in many species, including humans (11). The highly selective a, agonist SE 587, which easily penetrates the blood-brain barrier, displays significant anticonvulsant activity in both epileptic gerbils (33) and in rats with spontaneous petit mal-like seizures (39).
The present study was undertaken to determine whether the a,-adrenergic system can modulate the somatostatinergic system in the rat frontoptietal cortex. Therefore, we used phenylephrine, an cr,-adrenoceptor agonist, and prazosin, an rw,-adreno- ' Requests for reprints should be addressed to Eduardo Arilla. ) ; and carrier-free Na'*'I (IMS 30, 100 mCi/ml) from the Radiochemical Centre (Amersham, UK). [Tyr"]SS was radioiodinated by the chloramine-T method (21). The tracer was purified on a Sephadex G-25 coarse column (1 x lOO), which had been equilibrated with 0.1 M acetic acid, containing BSA 0.1% (w/v). Specific tracer radioactivity was about 600 Wmmol. The rabbit antibody used in the radioimmunoassay technique was purchased from the Radiochemical Centre. This antiserum was raised in rabbits against SS-14 conjugated to BSA and is specific for SS, but because SS-14 also constitutes the C-terminal portions of both SS-25 and SS-28, the antiserum does not distinguish between these three forms. Crossreactivity with other peptides was less than 0.5%. Cross-reaction with several SS analogues demonstrated that neither the N-terminal glycine nor the C-terminal cysteine residue is required for antibody binding, suggesting that the antigen site is directed towards the central part of the molecule containing the tryptophan residue. The binding of SS-14 to its antibody does not depend on an intact disulfide bond in the molecule, because breaking of the disulfide bond by reaction with 0.1% mercaptoethanol (boiling water bath, 5 min) did not change peptide immunoreactivity.
Experimental Animals
The animals used in this study were Sprague-Dawley rats (n = 60) weighing between 200 and 250 g. Rats were maintained on a 12-h light/dark cycle (0700-1900 h) and allowed free access to food. Phenylephrine (0.5,2, and 4 mg/kg> and prazosin (5,20, and 25 mg/kg) were dissolved in distilled water or propylene glycol 25%, respectively, as previously described (5,6). Fresh solutions were prepared every day just prior to administration. Drugs were diluted such that injections were in volumes of 2.0 ml/rat and were administered IP 7 h (phenylephrine) or 8 h (prazosin) prior to assay. In another experimental group, prazosin (20 mg/kg, IP) was administered 1 h before phenylephrine (2 mg/kg, IP). Control animals for each group cited were injected with equivalent volumes of distilled water, propylene glycol 25%, or propylene glycol 25% plus distilled water according to whether the corresponding experimental group was to be injected with phenylephrine, prazosin, or prazosin plus phenylephrine, respectively. Drug doses were selected according to the effective dose reported in previous studies (5,6). Rats were killed by decapitation at 7 or 8 h after the last injection, as appropriate. The brain was rapidly removed and the frontoparietal cortex was dissected over ice according to the method of Glowinski and Iversen (20) .
Tissue Extraction and SS Radioimmunoassay
For SS-LI measurements, the frontoparietal cortex was rapidly homogenized using a Brinkman polytron (setting 5, 30 s), in 1 ml 2 M acetic acid. Extracts were boiled for 5 min in a water bath, chilled in ice, and aliquots (100 ~1) were removed for protein determination (34). Subsequently, homogenates were centrifuged at 15,000 x g for 15 min at 4"C, and the supematant was neutralized with 2 M NaOH. Extracts were immediately stored at -70°C until assay. SS-LI level was determined in tissue extracts by a modified radioimmunoassay method (45), with a sensitivity limit of 10 pg/ml. Incubation tubes prepared in duplicate contained lOO+l samples of unknown or standard solutions of O-500 pg cyclic SS tetradecapeptide diluted in phosphate buffer (0.05 M, pH 7.2 containing 0.3% BSA, 0.01 M EDTA), 200 ~1 of appropriately diluted antiserum, 100 ~1 of freshly prepared ['*'I][Tyr"]SS diluted in buffer to give 6000 cpm/assay tube (equivalent to 5-10 pg), and enough buffer to give a final volume of 0.8 ml. All reagents as well as the assay tubes were kept chilled on ice before incubation at 4°C for 48 h. Separation of bound and free hormone was accomplished by the addition of 1 ml dextrancoated charcoal (dextran T70: 0.2% w/v, Pharmacia, Uppsala, Sweden; charcoal: Norit A 2% w/v, Serva, Feinbiochemica, Heidelberg, Germany). Dilution curve for this brain area was parallel to the standard curve. The intra-and interassay variation coefficients were 6.8% and 8.1%, respectively.
Binding Assay for Membrane Preparations
Frontoparietal cortex membranes were prepared as described by Reubi at 3O"C, membrane-bound peptide was isolated by centrifugation at 11,000 x g for 2 min, and radioactivity was determined in a Kontron gamma counter. Specific binding was defined as the difference in the amount of radioligand bound in the absence and presence of lo-' M SS.
Evaluation of Radiolabeled Peptide Degradation
To determine the extent of tracer degradation during incubation, we measured the ability of preincubated peptide to bind to fresh frontoparietal cortex membranes as previously described (1). Briefly, ['*'I][Tyr"]SS (250 PM) was incubated with membranes from rat frontoparietal cortex (0.15 mg protein/ml) for 60 min at 30°C. After this preincubation, aliquots of the medium were added to fresh membranes and incubated for an additional 60 min at 30°C. The fraction of the added radiolabeled peptide, which was specifically bound during the second incubation, was measured and expressed as a percentage of the binding that had been obtained in control experiments performed in the absence of membranes during the preincubation period.
Adenylate Cyclase Assay
The AC activity was measured as previously reported (25) with minor modifications (22). Briefly, rat frontoparietal cortex membranes (0.06 mg/ml) were incubated with 1.5 mM ATP, 5 n&f MgSO,, 10 ,u&f GTP, an ATP-regenerating system (7.5 mg/ ml creatine phosphate and 1 mg/ml creatine kinase), 1 mM IBMX, 0.1 mkf PMSF, 1 mg/ml bacitracin, 1 m&f EDTA, and test substances ( 10m4 M SS or lo-' M FK) in 0.1 ml of 0.025 M triethanolamine-HCl buffer (pH 7.4). After 15min incubation at 3O"C, the reaction was stopped by heating the mixture for 3 min. After refrigeration, 0.2 ml of an alumina slurry (0.75 g/ml in triethanolamine-HCl buffer, pH 7.4) was added and the suspension was centrifuged. The supematant was taken to assay the cyclic AMP (CAMP) by using the method of Gilman (19) . The SS concentration used was the one that is known to inhibit rat (42,54) and human (18) brain AC. FK was used at a concentration of 10e5 M, which primarily stimulates the catalytic subunit of AC (55).
Pertussis Toxin-Catalyzed ADP Ribosylation
The PTX-catalyzed ADP ribosylation was carried out as previously reported (7). After PTX activation, membranes (0.8 mg of protein/ml) were incub,ated with PTX (16 pg/ml) in 100 mM Tris-Cl buffer (pH 8.0), containing 10 mM thymidine, 1 mM ATP, 100 /JM GTP, 2.51 rnkf MgC&, 1 mkl EDTA, 1 /&f ['*PINAD+ (30 Wmmol), and an ATP-regenerating system. After 30 min at 30°C the reaction was stopped by addition of 1 ml of ice-cold 100 miU Tris-HCl buffer (pH 8.0), sedimented by centrifugation for 10 min at 30,000 X g and the pellet was solubilized with 0.1 ml of CD n&f Tris-HCl buffer (pH 6.8) containing 10% glycerol, 0.001% bromophenol blue, and 3% SDS (SDS sample buffer). After heating for 30 min at 6O'C, the suspension was centrifuged for 10 min at 100,000 X g and aliquots of the supematant were submitted to SDS-PAGE, using the procedure of Laemmli (31) as previously described (30). The gels were run, fixed, dried, and exposed to DuPont films (cronex 4) for l-7 days at -8O"C, using an intensifying screen.
Data Analysis
The LIGAND computer program (41) was used to analyze the binding data. The use of this program enabled models of receptors that best fit a given set of binding data to be selected. The same program was also used to present data in the form of Scatchard plots (53) and to compute values for receptor affinity (K,,) and density (B,,,) that best fit the sets of binding data for each rat. Statistical comparisons of all the data were carried out with one-way analysis of variance (ANOVA) and the Student's Newman-Keuls test. Means among groups were considered significantly different when p < 0.05. Each individual experiment was performed in duplicate.
RESULTS
The specific binding of ['251][Tyr"]SS to membranes from rat frontoparietal cortex in all rat groups bound ['*'I][Tyr' ']SS in a time-dependent fashion; an apparent equilibrium was observed between 50 and 180 min at 30°C (data not shown). All subsequent binding experiments were therefore conducted at 30°C for 60 min. Peptide degradation was determined to rule out the possibility of different SS-degrading activities in all the preparations that might have affected the interpretation of the results. Membranes from frontoparietal cortex showed a similar peptide degradation capacity, and the values varied by no more than 10% in all the experimental groups.
Phenylephrine administration at a dose of 2 or 4 mg/kg produced a significant decrease in ["'I][Tyr"]SS binding to rat frontoparietal cortex membranes compared with controls, with no difference detected between both doses (Table 1 and Fig. 1, left  panel) . This decrease was due to a decrease in the number of SS receptors as revealed by Scatchard plots of the binding data (Fig.  1, right panel) . In addition, a significant increase in the affinity of these receptors was observed at both of these doses (Table 1) . No changes in the SS receptor number and affinity were observed at the lowest dose studied (Table 1) . Therefore, subsequent studies were carried out with 2 mg/kg, the dose frequently used by other investigators (5,6).
Prazosin administration at a dose of 20 or 25 mg/kg significantly increased [ tex membranes compared with controls, with no difference detected between both doses (Table 1 and Fig. 2, left panel) . This increase was due to a rise in the maximum number of SS receptors as revealed by Scatchard plots of the binding data (Fig. 2,  right panel) . In addition, a significant decrease in the affinity of these receptors was observed at both of these doses (Table 1) .
No changes in the SS receptor number and affinity were observed at the lowest dose studied (Table 1) . Therefore, subsequent studies were carried out with 20 mg/kg, a dose frequently used by other investigators (56). Pretreatment with prazosin (20 mg/kg) completely blocked the changes in the number and affinity constant of SS receptors induced by phenylephrine (2 mg/kg) administration (Table 1 and Fig. 3) .
To assess whether phenylephrine or prazosin exert a direct action on SS receptors, 10m5 M phenylephrine or prazosin was included in the incubation medium at the time of the binding assay with membranes from frontoparietal cortex of normal rats. The addition of phenylephrine or prazosin to the incubation medium changed neither the number nor the affinity of the SS receptors (data not shown).
In the brain, SS binds to its specific receptors and regulates the AC system via guanine nucleotide binding regulatory proteins (G-proteins), which are sensitive to PTX (l&42,60). Therefore, we studied the PTX substrates in frontoparietal cortex after the treatment with phenylephrine and prazosin. PTX induced the incorporation of "P in a 41 kDa (G,,) and 39 kDa (G,,) protein under the conditions studied here (Fig. 4 ). Phenylephrine and prazosin had no effect on the PTX-catalyzed ADP ribosylation of Gi and G, a subunits (Fig. 4) .
To study SS-modulated AC activity, frontoparietal membranes were incubated with SS (lo-" M), with or without FK (lo-' M), a direct AC activator. No significant differences in basal or FK-stimulated AC activity were observed between the control, phenylephrine, prazosin, and prazosin plus phenylephrine groups in frontoparietal cortex membranes (Table 2) . In all experimental groups, SS inhibited the basal and the FK-stimulated AC activities. The treatment with phenylephrine and/or prazosin did not modify the capacity of SS to inhibit the basal and FK-stimulated AC activity, in comparison with the respective control groups ( Table 2) .
The administration of either phenylephrine, prazosin, and/or prazosin plus phenylephrine did not affect SS-LI content in frontoparietal cortex in comparison with the respective control group (Table 1) .
DISCUSSION
This study indicates that the administration of phenylephrine decreased the number of specific SS receptors in the frontoparietal cortex, while increasing receptor affinity. Pretreatment with the cu,-adrenergic antagonist prazosin prevented the phenylephrine-induced changes in the binding of SS, whereas prazosin alone increased SS binding to its receptor.
In previous studies, the time course of the phenylephrine and prazosin effect on the binding of steroid ligand to estrogen ($6) and progestin receptors (38), it was found that in several regions of the CNS of adult rats the change in the number of specific receptors was first detectable at 7 or 8 h after a single injection; at 16 h, the number of specific receptors had returned to baseline levels. In the present study, the treatment intervals were selected according to these studies. The phenylephrine and prazosin doses selected in the present study are similar to those used by other authors (5.6).
The levels of SS-LI in the frontoparietal cortex as well as the binding parameters of the SS receptors in this brain area in the control rats were similar to those previously reported (16,47,51,57). Although the Scatchard plots appear to be linear, this is no proof for receptor homogeneity.
Indeed, it has been demonstrated for many years that SS binding in rat brain is heterogeneous (43,53). It has been demonstrated recently that there are five cloned receptors expressed in the brain and that all have a similar high affinity for SS (3,10). Thus, a linear Scatchard plot indicates only that the labeled sites have a similar affinity for the radioligand used.
The stimulation of (Y, adrenoceptors primarily stimulates the phospholipase C-catalyzed breakdown of phosphoinositides, leading to the generation of inositol triphosphate and diacylgly- cerol (38) . A series of recent reports has suggested that diacylglycerol derived from phosphatidylinositol breakdown is directly involved in the transmemb:rane control of protein phosphorylation through the activation of protein kinase C (43). It is tempting to speculate that the decrease in labeled SS binding induced by activation of a, adrenoceptors might be a consequence of the activation of protein kinase C by diacylglycerol.
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In this regard, Matozaki et al. (36) have re.ported that diacylglycerol modulates SS binding to its receptors on rat pancreatic acinar cell membranes.
In our experiments, SS inhibited frontoparietal cortex AC activity in rats, a finding that is in agreement with the literature (35,42,54). A relatively high concentration of SS (10e4 h4) is required to produce inhibition. Other authors (4,18,42,54) used the same concentration in their studies on SS inhibition of human and rat brain AC. There is evidence suggesting that the effect of SS on AC activity is receptlor mediated, rather than being a nonspecific inhibitory effect.
The SS concentration necessary to elicit the maximal inhibition of AC activity was about threefold that necessary to displace ["'I][Tyr"]SS binding to its receptors. This apparent discrepancy may be explained observing that the PTX-sensitive G-proteins can modulate the affinity of SS receptors and/or the receptor coupling to the transduction system (AC among others). In this respect, Enjalbert et al. (14) imd Koch and Schonbrunn (28) have shown that GTP-induced mobilization of the G-protein reduces SS receptor affinity of the neuropeptide in cerebral cortical cells and in GH,C, pituitary cell clones.
The changes in the number of SS receptors following agonist or antagonist cu,-adrenoceptor administration was not accompanied by a corresponding modification in SS-inhibited AC activity. Some of these receptors are coupled by PTXsensitive guanine nucleotide binding proteins (G-proteins) to a variety of cellular effector systems and mediate the inhibition by SS of AC (48,54) and voltage-sensitive Ca2+ channel activity (63), as well as stimulation of K+ channel activity (62). Other cellular actions of SS, including its antiproliferative effects (61) and regulation of Na+/H+ exchange (2), appear to be mediated by PTX-insensitive mechanisms, indicating heterogeneity of receptor-effector interactions.
Therefore, it is possible that the SS receptors modified by the (Y,-adrenergic system have not been functionally coupled to guanine nucleotide regulatory protein G,, and may represent spare receptors, or a subpopulation of SS receptors that are coupled to an alternative second messenger system.
An inconsistency between changes in receptors and signal transduction is not unprecedented. For example, chronic exposure of primary cultures of mouse cortical neurons to the muscarinic antagonist atropine has been shown to increase the density of muscarinic receptors while decreasing carbacholstimulated phosphoinositide hydrolysis (56). Alternatively, the lack of correlation between the magnitude of SS inhibition 
